Literature DB >> 28288594

Laparoscopic resection of neuroblastomas in low- to high-risk patients without image-defined risk factors is safe and feasible.

Chiyoe Shirota1, Takahisa Tainaka1, Hiroo Uchida2, Akinari Hinoki1, Kosuke Chiba1, Yujiro Tanaka1.   

Abstract

BACKGROUND: Several studies have reported that minimally invasive surgery (MIS) might be considered for resecting neuroblastomas without image-defined risk factors (IDRFs); however, there are no studies comparing the outcomes of laparotomy and laparoscopy in IDRF-negative patients. Thus, we investigated the feasibility of laparoscopic surgery and compared the two abovementioned approaches.
METHODS: To compare the effects of laparotomy with those of laparoscopy in patients with neuroblastomas without IDRFs, the following items were retrospectively compared: largest tumor dimension, volume of blood loss, time required to initiate postoperative feeding, locoregional recurrence rate, survival, etc.
RESULTS: Nine patients without IDRFs (three at low-to-medium risk and six at high risk) underwent laparotomy, and seven patients without IDRFs (two at low-to-medium risk and five at high risk) underwent laparoscopy. Median duration of surgery was 221 (130-304) and 172 (122-253) min in the laparotomy and laparoscopy groups, respectively, showing no significant difference. Median postoperative time required for resuming meal consumption was significantly longer in the laparotomy (4 days; 2-5) group than that in the laparoscopy group (3 days; 2-3; p = 0.023). Median blood loss was significantly higher in the laparotomy group (5 ml/Kg;2.6-16) than that in the laparoscopy group (2.1 ml/Kg;0.1-4.0; P = 0.037). Median follow-up period was 81 (52-94) and 21 (17-28) months, locoregional recurrence rates were 22 and 0% at 1 year, 1-year progression-free survival rates were 78 and 100%, and overall survival rates were 67 and 100% in the laparotomy and laparoscopy groups, respectively, with no significant differences.
CONCLUSIONS: MIS for the treatment of neuroblastomas without IDRFs in low- to high-risk patients is safe and feasible and does not compromise the treatment outcome.

Entities:  

Keywords:  Image-defined risk factors; Laparoscopy; Minimally invasive surgery; Neuroblastoma

Mesh:

Year:  2017        PMID: 28288594      PMCID: PMC5348921          DOI: 10.1186/s12887-017-0826-8

Source DB:  PubMed          Journal:  BMC Pediatr        ISSN: 1471-2431            Impact factor:   2.125


Background

Neuroblastoma is a common malignant solid tumor in pediatric cases that is usually treated by a combination of observation, surgery, chemotherapy and radiation therapy. Surgical resection is a part of the multidisciplinary approach, for which it is important to decrease the general invasiveness and damage to the surrounding tissues and promptly transition to subsequent treatments [1-3]. Image-defined risk factors (IDRFs) are surgical risk factors that are evaluated according to the concepts established by the International Neuroblastoma Risk Group, as proposed by collaborative studies conducted in Europe [4, 5]. The significance of preoperative evaluation of surgical risks by internationally integrated standards that are made possible by IDRFs is remarkable, and the establishment of standardized criteria for and assessment of not only the advisability of surgery but also the selection of surgical procedure is expected. The prevalence of clinical studies on surgery using IDRFs is anticipated to increase in future. Compared with laparotomy, laparoscopic surgery is generally associated with rapid recovery and less invasiveness [6, 7]. Laparoscopic surgical resection for selected pediatric malignant solid tumors was found to be both feasible and safe [8, 9]. Long-term follow-up data are essential to confirm its oncologic safety [10], and several reports have claimed that minimally invasive surgery (MIS) might be considered to resect neuroblastomas without IDRFs [11, 12]. Minimally invasive adrenalectomy is a promising approach for the resection of small adrenal tumors, and benign diseases are excellent candidates for this minimally invasive technique [13]. However, there have been no studies comparing laparotomy and laparoscopy for the treatment of neuroblastomas in low- to high-risk patients without IDRFs. Thus, we investigated the feasibility of laparoscopic surgery and attempted to compare both these approaches in IDRF-negative patients.

Methods

Prior to this study, all protocols were approved by the ethics review board of our institute (approval number: 2015–0086). The medical records of all patients aged 0–15 years who underwent total or partial resection of abdominal neuroblastoma at our department between August 2003 and August 2016 were retrospectively reviewed. Laparoscopic resection was introduced in February 2014 and was chosen when the tumor had no IDRF-positive factor except contact with renal vessels. Determination of the therapeutic strategy was based on the Japan Neuroblastoma Study Group (JNBSG) protocol, where surgical intervention was considered when the patients achieved IDRF-negative status and had no metastatic lesions [14-16]. To evaluate the effects of laparoscopic surgery, patients with neuroblastomas without IDRFs who underwent laparotomy were compared with those who underwent laparoscopy. The following items were retrospectively compared: N-myc proto-oncogene protein (MYCN), vanillylmandelic acid (VMA), homovanillic acid (HVA), neuron-specific enolase (NSE), largest tumor dimension, duration of surgery, volume of blood loss, time required to initiate postoperative feeding, locoregional recurrence rate and survival. Statistical analysis was performed using the Fisher’s exact test for categorical variables and Wilcoxon’s signed-ranktest for continuous variables with JUMP pro ® 11 (SAS Institute Inc., Cary, NC, USA). A p-value of <0.05 was considered statistically significant.

Surgical laparoscopic procedure

The patient was placed in the supine or semi-lateral decubitus position, three flaps were created in the umbilicus in an inverted Y shape, a multi-port device was inserted, and the first port was placed [17]. Through the multi-port device, one or two additional ports and one or two working ports were inserted in the abdomen, and abdominal air pressure of 8–10 mmHg was applied. Resection was performed using laparoscopic coagulating shears. Then, the resected tumor was placed in a specimen retrieval bag and removed through the umbilical layer if it was 5 cm or less in diameter or by performing an additional Pfannenstiel incision if larger.

Results

Thirty-four patients (six at low-to-medium risk and 28 at high risk) underwent laparotomy, and nine patients (two at low-to-medium risk and seven at high-risk) underwent laparoscopy. The proportion of IDRF-negative patients in the laparoscopy group was significantly greater than that in the laparotomy group (78% vs. 26%; p = 0.008). No differences in sex, age, MYCN, VMA, HVA, NSE or tumor size (largest tumor dimension) were apparent between the groups. Only one of the two IDRF positive case was converted to laparotomy (Table 1).
Table 1

Resection of abdominal neuroblastoma performed between August 2003 and 2016

Laparotomy (n = 34)Laparoscopy (n = 9) p
Total laparoscopic resection 8 (89%)Conversion 1 (11%)
RemovalTotal 18 (53%)Partial 16 (47%)Total 8 (100%)Partial 1 (100%)
Age (months) a 45 [12–60]28 [21.5–51]0.300
Sexmales 12 (35%)females 22 (65%)males 5 (56%)females 4 (44%)0.440
IDRF (%)IDRF+ 25 (74%)IDRF− 9 (26%)IDRF+ 2 (22%)IDRF− 7 (78%) 0.008 b
MYCN amplifiedamplified 9 (26%), single 14 (41%), unknown 11 (32%)amplified 2 (22%), single 3 (33%), unknown 4 (44%)0.790
HVA (mg/gCr) a 16.1 [13.1–23.8]18.2 [11.2–43.3]0.702
VMA (mg/gCr) a 9.70 [8.9–17.8]9.1 [4.0–24.7]0.702
NSE (ng/mL) a 11.4 [9.0–15.7]19.1 [11.0–21.0]0.051
Largest tumor dimension (cm) a 4.0 [3.0–6.0]4.3 [2.6–4.8]0.704

IDRF image-defined risk factor, MYCN N-myc proto-oncogene protein, VMA vanillylmandelic acid, HVA homovanillic acid, NSE neuron-specific enolase

aMedian [Interquartile range]

bThis p value shows that the proportion of IDRF-negative patients in the laparoscopy group was significantly greater than that in the laparotomy group

Resection of abdominal neuroblastoma performed between August 2003 and 2016 IDRF image-defined risk factor, MYCN N-myc proto-oncogene protein, VMA vanillylmandelic acid, HVA homovanillic acid, NSE neuron-specific enolase aMedian [Interquartile range] bThis p value shows that the proportion of IDRF-negative patients in the laparoscopy group was significantly greater than that in the laparotomy group In the laparotomy group, total resection was performed in nine out of 25 IDRF-positive patients; partial resection was performed in the remaining 16 (Fig. 1).
Fig. 1

Patient and risk-group stratifications

Patient and risk-group stratifications In the laparoscopic group, one of two IDRF-positive patients was converted from laparoscopy to laparotomy during the course of the procedure; dissection was difficult because of strong adhesions around the renal vessels. IDRF was positive in this case, and the renal artery was encased by the tumor so he underwent laparotomy with partial resection. The other IDRF-positive patient underwent laparoscopy with total resection (Fig. 2).
Fig. 2

A 51-month-old girl (International Neuroblastoma Staging System [INSS]: stage 4, Children’s Oncology Group [COG] risk: high, surgical duration: 202 min, and blood loss: 3 mL). Total resection was laparoscopically performed. On her first visit, imaging studies showed that the renal vessels and aorta were encased by the tumor. After neoadjuvant chemotherapy, the tumor was seen to be in contact with the right renal vessels only. Outcome: progression-free survival, 23 months

A 51-month-old girl (International Neuroblastoma Staging System [INSS]: stage 4, Children’s Oncology Group [COG] risk: high, surgical duration: 202 min, and blood loss: 3 mL). Total resection was laparoscopically performed. On her first visit, imaging studies showed that the renal vessels and aorta were encased by the tumor. After neoadjuvant chemotherapy, the tumor was seen to be in contact with the right renal vessels only. Outcome: progression-free survival, 23 months Nine IDRF-negative patients (three at low-to-medium risk and six at high risk) underwent laparotomy, and seven IDRF-negative patients (two at low-to-medium risk and five at high risk) underwent laparoscopy (Fig. 1), and the outcomes were compared between the two groups. Seven of the 9 cases in the laparotomy group and 5 of the 7 cases in the laparoscopy group received neoadjuvant chemotherapy, consisting of vincristine, cyclophosphamide, ifosfamide, doxorubicin, pirarubicin, cisplatin, carboplatin and etoposide, based on the JNBSG risk-matched multidrug regimen. Total resection was performed in all patients. There were apparent differences in age, sex, body weight, Kaup index, MYCN, VMA, HVA, NSE and tumor size (largest tumor dimension) between the groups. The following items were compared between IDRF-negative patients who underwent laparotomy (n = 9) or laparoscopy (n = 7): duration of surgery, volume of blood loss, time required for initiating postoperative meal consumption, locoregional recurrence at 1 year, and survival. The median duration of surgery was 221 min (130–304) in the laparotomy group and 172 min (122–253; p = 0.626) in the laparoscopy group, indicating no significant difference. The median duration to resume meal consumption was significantly longer in the laparotomy group (4 days; 2–5) than that in the laparoscopy group (3 days; 2–3; p = 0.023). The median volume of blood loss was significantly higher in the laparotomy group (5 mL/kg body weight; 2.6–16) than that in the laparoscopy group (2.1 mL/kg body weight; 0.1–4.0; p = 0.037). The median follow-up period was 81 and 21 months, locoregional recurrence rates at 1 year were 22% (2 of 9 cases) and 0%, 1-year progression-free survival rates were 78 and 100%, and overall survival rates were 67 and 100% in the laparotomy and laparoscopy groups, respectively, indicating no significant differences (Table 2). No surgical complications (greater than Grade II severity, according to the Dindo classification) were observed in the IDRF-negative group [18].
Table 2

Characteristics of IDRF-negative patients who underwent laparotomy or laparoscopic tumor resection

Laparotomy (n = 9)Laparoscopic surgery (n = 7) p
RiskLow/intermediate 3 (33%)High 6 (67%)Low/intermediate 2 (29%)High 5 (71%)0.838
Surgerytotal removal 9 (100%)total removal 7 (100%)
Age (month) a 12 [9.5–48]28 [23–51]0.143
Sexmale 6 (67%)female 3 (33%)male 3 (43%)female 4 (57%)0.615
Body weight (kg) a 8.65 [8.09–15.2]11.8 [10.3–14.9]0.143
Kaup index a 15.32 [13.87–16.65]15.67 [15.51–16.45]0.626
MYCN amplifiedamplified 2 (22%), single copy 2 (22%), unknown 5 (56%)amplified 2 (29%), single copy 2 (29%), unknown 3 (43%)0.771
VMA (mg/gCr) a 11.1 [9.6–17.0]9.1 [7.8–19.8]0.805
HVA (mg/gCr) a 21 [17.7–30.3]18.2 [11.2–30.4]0.805
NSE (ng/mL) a 9.6 [8.0–29.4]19.3 [12.4–21.0]0.326
Largest tumor dimension at surgery (cm) a 3.3 [2.9–4.1]3.6 [2.7–5.0]0.626
Duration of surgery (min) a 221 [130–304]172 [122–253]0.626
Loss of blood volume (mL/kg) a 5 [2.6–16] 2.1 [0.1–4.0] 0.037 b
Time to start postoperative feeding (days) a 4 [2–5] 3 [2–3] 0.023 b
Locoregional recurrence (1 year)22%0%0.475
Progression-free survival (1 year)78%100%0.414
Overall survival (1 year)67%100%0.231
Follow up (months) a 81 [52–94]21 [17–28]

IDRF image-defined risk factor, MYCN N-myc proto-oncogene protein, VMA vanillylmandelic acid, HVA homovanillic acid, NSE neuron-specific enolase

aMedian [Interquartile range] bSignificant differences

Characteristics of IDRF-negative patients who underwent laparotomy or laparoscopic tumor resection IDRF image-defined risk factor, MYCN N-myc proto-oncogene protein, VMA vanillylmandelic acid, HVA homovanillic acid, NSE neuron-specific enolase aMedian [Interquartile range] bSignificant differences Comparing conditions between the initial visit and pre-surgery (after neoadjuvant therapy) among the IDRF-negative patients, we found that the tumor size markedly decreased at pre-surgery (3.4 cm; range, 1.1–8.7; p = 0.031) compared with the initial visit (5.2 cm; range, 3.1–11.3). In addition, five patients who underwent laparoscopic resection transitioned from IDRF-positive to IDRF-negative after chemotherapy. For example, in Case 1 (a 28-month-old male at high risk), although the tumor was found to envelop the renal vessels at the initial visit, the tumor size markedly decreased (from 9.0 cm to 4.6 cm) and IDRFs were absent on imaging after chemotherapy (Fig. 3). This patient remained progression-free for 24 months after laparoscopic surgery. In Case 2 (a 51-month-old male at low risk), the tumor size was 8.7 cm and IDRFs were absent; thus, we performed laparoscopic total excision and removed the tumor through a Pfannenstiel incision without any complication (Fig. 4). This patient remained progression-free for 16 months after surgery.
Fig. 3

(Case 1): A 28-month-old boy (International Neuroblastoma Staging System [INSS]: stage 4, Children’s Oncology Group [COG] risk: high, surgical duration: 146 min, and blood loss: 53 mL). Total resection was laparoscopically performed. Outcome: progression-free survival, 24 months

Fig. 4

[Case 2 (pre-surgery)]: A 51-month-old boy (International Neuroblastoma Staging System [INSS]: stage 1, Children’s Oncology Group [COG] risk: low, surgical duration: 253 min, and blood loss: 61 mL). Total resection was laparoscopically performed. The tumor was in contact with the aorta, but renal vessels were intact. Outcome: progression-free survival, 16 months

(Case 1): A 28-month-old boy (International Neuroblastoma Staging System [INSS]: stage 4, Children’s Oncology Group [COG] risk: high, surgical duration: 146 min, and blood loss: 53 mL). Total resection was laparoscopically performed. Outcome: progression-free survival, 24 months [Case 2 (pre-surgery)]: A 51-month-old boy (International Neuroblastoma Staging System [INSS]: stage 1, Children’s Oncology Group [COG] risk: low, surgical duration: 253 min, and blood loss: 61 mL). Total resection was laparoscopically performed. The tumor was in contact with the aorta, but renal vessels were intact. Outcome: progression-free survival, 16 months

Discussion

The advantages of MIS compared with those of open surgery, include marked reduction in postoperative pain and surgical site infection, and cosmesis [19]. Accordingly, there were significant differences in the volume of blood loss and time required to initiate postoperative feeding between laparotomy and laparoscopy for IDRF-negative patients. Thus, we considered that laparoscopy was feasible for IDRF-negative patients. However, the tumor size limit for laparoscopic excision is unclear, and most reports have supported the indication of laparoscopic excision for tumors <4–6 cm [7, 20, 21]. In our laparoscopic IDRF-negative cases, the tumor sizes at operation were 1.1, 2.7, 2.8, 3.6, 4.6, 5.0 and 8.7 cm. Because no obvious vascular involvement was present, we determined that the patient (Case 2) could undergo laparoscopic total resection and proceeded with the surgery. Five patients who underwent laparoscopic resection transitioned to IDRF-negative after chemotherapy. This finding indicates the importance of the timing of surgery in advanced cases. Simon et al. reported that 246 of 278 patients with stage 4 neuroblastoma aged 18 months or older did not undergo surgery prior to chemotherapy [22]. Kelleher et al. compared the clinical outcomes between laparotomy and laparoscopy, including advanced cases and found no difference in mortality among patients who met the selection criteria for the laparoscopic resection which were absence of vascular encasement and size <5 cm as the greatest dimension. Other patients underwent laparotomy [19, 23]. We performed neuroblastoma resection in 13 patients after introducing laparoscopic surgery, and of these, four underwent laparotomy (all were IDRF-positive) and nine underwent laparoscopy (two IDRF positive for contact with or encasement of renal vessels and seven IDRF negative). One IDRF-positive patient with encasement of renal vessels was converted from laparoscopy to laparotomy because dissection appeared difficult owing to strong adhesion with renal vessels. Partial resection under laparotomy was performed in this patient, and we had to carefully determine the indication for laparoscopy, considering the obvious vascular involvement in this case. The tumor in the other IDRF-positive patient made contact with the renal vessels and inferior vena cava; however, dissection was possible by laparoscopic surgery, and total tumor resection was macroscopically performed. Furthermore, a negative margin was histopathologically diagnosed. This patient currently remains progression-free for 23 months after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Although IDRF is positive if renal vessels are not only encased but also in contact with the tumor, in our experience, laparoscopic surgery could potentially be used for contacted cases [11]. Thus, we still considered IDRF in renal vessels as IDRF-negative. Irtan et al. reported that the completeness resection was related only to the number of preoperative IDRFs. They treated patients according to ongoing SIOPEN protocols, which included a high-risk group who received high-dose chemotherapy followed by stem cell rescue before surgery. They suggested IDRF assessment after neoadjuvant chemotherapy is useful in these patients [24]. Another advantage of laparoscopic surgery is a reduced risk of intestinal obstruction, which is critical for pediatric oncology patients, especially if they receive radiotherapy [25]. In our study, all patients in the laparoscopy group started oral feeding within 3 days after surgery and no patients presented symptoms of ileus. However, we had too few cases to prove the competitive advantage of laparoscopy over laparotomy. The results of the present study showed no differences in short-term prognosis between these two procedures; thus, we believe that laparoscopic surgery can achieve favorable outcomes comparable to those of laparotomy in IDRF-negative patients, even those considered at high risk. This study was limited by its small sample size and short observation period. Future studies involving more patients and a longer follow-up period are warranted. Moreover, because this was a single-center, retrospective study, a multicenter, prospective study would be ideal to assess the merits of minimally invasive surgery for this patient population. This is the first report for the treatment of neuroblastoma comparing laparotomy and laparoscopy for the treatment of neuroblastoma without IDRFs.

Conclusions

Although the limited number of cases and short-term observation period prevented the investigation of long-term outcomes, we found that laparoscopic surgery was a feasible minimally invasive procedure for the resection of neuroblastoma, particularly in IDRF-negative patients. Further studies focused on oncologic and safety outcomes are warranted to assess the merits of this surgical approach in neuroblastomas.
  25 in total

1.  Surgical treatment for abdominal neuroblastoma in the laparoscopic era.

Authors:  T Iwanaka; M Arai; M Ito; H Kawashima; K Yamamoto; R Hanada; S Imaizumi
Journal:  Surg Endosc       Date:  2001-04-03       Impact factor: 4.584

2.  Histologic survey of neuroblastomas after intensive induction chemotherapy.

Authors:  Yoshiaki Tsuchida; Jun Miyauchi; Minoru Kuroiwa; Norio Suzuki; Jun Sakamoto; Makoto Suzuki; Toshiji Shitara
Journal:  Pediatr Blood Cancer       Date:  2005-10-15       Impact factor: 3.167

3.  Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma.

Authors:  M Kaneko; Y Tsuchida; J Uchino; T Takeda; M Iwafuchi; N Ohnuma; H Mugishima; J Yokoyama; H Nishihira; K Nakada; S Sasaki; T Sawada; K Kawa; N Nagahara; S Suita; S Sawaguchi
Journal:  J Pediatr Hematol Oncol       Date:  1999 May-Jun       Impact factor: 1.289

Review 4.  Minimally invasive surgery versus open surgery for the treatment of solid abdominal and thoracic neoplasms in children.

Authors:  Manou S de Lijster; Rosemarijn M Bergevoet; Elvira C van Dalen; Erna Mc Michiels; Huib N Caron; Leontien Cm Kremer; Daniel C Aronson
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

5.  Surgical treatment of neuroblastoma: twenty-three years of experience at a single institution.

Authors:  A I Koivusalo; M P Pakarinen; R J Rintala; U M Saarinen-Pihkala
Journal:  Surg Today       Date:  2013-04-12       Impact factor: 2.549

6.  Laparoscopic adrenal surgery for neuroblastomas in children.

Authors:  P de Lagausie; D Berrebi; J Michon; P Philippe-Chomette; A El Ghoneimi; C Garel; H Brisse; M Peuchmaur; Y Aigrain
Journal:  J Urol       Date:  2003-09       Impact factor: 7.450

Review 7.  Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Authors:  G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

Review 8.  Pediatric minimally invasive surgery: laparoscopy and thoracoscopy in infants and children.

Authors:  Thane Blinman; Todd Ponsky
Journal:  Pediatrics       Date:  2012-08-06       Impact factor: 7.124

9.  Minimally invasive surgery of neuroblastic tumors in children: Indications depend on anatomical location and image-defined risk factors.

Authors:  Sabine Irtan; Hervé J Brisse; Véronique Minard-Colin; Gudrun Schleiermacher; Sandra Canale; Sabine Sarnacki
Journal:  Pediatr Blood Cancer       Date:  2014-10-04       Impact factor: 3.167

10.  The umbilical Benz incision for reduced port surgery in pediatric patients.

Authors:  Hizuru Amano; Hiroo Uchida; Hiroshi Kawashima; Kyoichi Deie; Naruhiko Murase; Satoshi Makita; Kazuki Yokota; Yujiro Tanaka
Journal:  JSLS       Date:  2015 Jan-Mar       Impact factor: 2.172

View more
  5 in total

1.  CO2 pneumoperitoneum effects on proliferation and apoptosis in two different neuroblastoma cell lines.

Authors:  Monica Currò; Salvatore Arena; Angela Simona Montalto; Patrizia Perrone; Donatella Di Fabrizio; Maria Paola Bertuccio; Carmelo Mazzeo; Daniela Caccamo; Riccardo Ientile; Carmelo Romeo; Pietro Impellizzeri
Journal:  Pediatr Surg Int       Date:  2022-01-27       Impact factor: 1.827

2.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17

3.  Two-stage laparoscopic resection of giant hepatoblastoma in infants combined with liver partial partition and artery ligation.

Authors:  Yaohao Wu; Lexiang Zeng; Ronglin Qiu; Jie Zhang; Jianhang Su; Minyi Liao; Xiaogeng Deng
Journal:  World J Surg Oncol       Date:  2021-02-25       Impact factor: 2.754

4.  Laparoscopic approach for abdominal neuroblastoma in Japan: results from nationwide multicenter survey.

Authors:  Takafumi Kawano; Ryota Souzaki; Wataru Sumida; Tetsuya Ishimaru; Jun Fujishiro; Tomoro Hishiki; Yoshiaki Kinoshita; Hiroshi Kawashima; Hiroo Uchida; Tatsuro Tajiri; Akihiro Yoneda; Takaharu Oue; Tatsuo Kuroda; Tsugumichi Koshinaga; Eiso Hiyama; Masaki Nio; Yukihiro Inomata; Tomoaki Taguchi; Satoshi Ieiri
Journal:  Surg Endosc       Date:  2021-06-18       Impact factor: 4.584

Review 5.  Advances in the Surgical Treatment of Neuroblastoma.

Authors:  Yan-Bing Luo; Xi-Chun Cui; Lin Yang; Da Zhang; Jia-Xiang Wang
Journal:  Chin Med J (Engl)       Date:  2018-10-05       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.